Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29629070 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL31614958 | 0.84 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL2064221 | 0.82 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL702012 | 0.80 | CES2 (0.37) | CES2CES1GABRA1GABRG2GABRB3 | |
| SCHEMBL30368120 | 0.80 | CES2 (0.37) | CES2CES1GABRA1GABRG2GABRB3 | |
| SCHEMBL11932846 | 0.80 | AXL (0.31) | — | |
| SCHEMBL31614969 | 0.80 | — | — | |
| SCHEMBL29279709 | 0.80 | MEP1B (0.37) | DRD4 | |
| SCHEMBL25049411 | 0.79 | CYP1A2 (0.31) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL30210991 | 0.79 | CYP1A2 (0.31) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083750-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC | 2026-03-26 | — | — | US | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4577214-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025090465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025077663-A1 | FUSED RING COMPOUND AND USE | 成都海博为药业有限公司 | 2025-04-17 | — | — | WO | disclosed |
| WO-2025077770-A1 | FUSED RING COMPOUND AND USE THEREOF IN KRAS INHIBITOR | 成都海博为药业有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4436571-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| CN-112300120-A | Compound for preparing balsalavir or derivatives thereof, preparation method and application thereof | 北京四环制药有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-109721585-B | Preparation method of baroxavir key intermediate | 浙江工业大学 | 2020-09-29 | — | — | CN | disclosed |
| CN-110790690-A | Synthetic method of 3, 4-difluoro-2- ((phenylthio) methyl) benzoic acid | 湖南师范大学 | 2020-02-14 | — | — | CN | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1551822-B1 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LILLY CO ELI (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY | 2005-11-24 | — | — | US | disclosed |
| EP-1551822-A2 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004009578-A2 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | CYP1A2 2936/4885CYP2D6 1712/4885CYP2C9 2512/4885 |
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | NR5A1, NR3C2, OXER1 | CYP1A2 829/4885CYP2D6 469/4885CYP2C9 916/4885 |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | CYP1A2 1296/4885CYP2D6 422/4885CYP2C9 904/4885 |
| US-20260083750-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | KRAS, NRAS, RASGRP1 | CYP1A2 4426/4885CYP2D6 3752/4885CYP2C9 3431/4885 |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | CYP1A2 3288/4885CYP2D6 2871/4885CYP2C9 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.